Aclaris Therapeutics (NASDAQ:ACRS) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research note issued to investors on Tuesday morning, MarketBeat.com reports. The firm issued an overweight rating on the biotechnology company’s stock.

Several other equities analysts have also issued reports on the stock. Jefferies Financial Group raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and boosted their price target for the company from $2.00 to $7.00 in a report on Tuesday, November 19th. Piper Sandler raised shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $3.00 to $13.00 in a report on Monday, November 18th. Leerink Partnrs raised shares of Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 19th. BTIG Research raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 target price for the company in a research note on Tuesday, November 19th. Finally, StockNews.com lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 8th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Aclaris Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

Aclaris Therapeutics Stock Performance

Shares of Aclaris Therapeutics stock opened at $1.58 on Tuesday. Aclaris Therapeutics has a 52 week low of $0.95 and a 52 week high of $5.17. The stock has a market capitalization of $170.51 million, a price-to-earnings ratio of -3.04 and a beta of 0.48. The firm has a fifty day moving average of $2.22 and a two-hundred day moving average of $2.21.

Hedge Funds Weigh In On Aclaris Therapeutics

Large investors have recently modified their holdings of the business. ExodusPoint Capital Management LP acquired a new position in shares of Aclaris Therapeutics during the 4th quarter worth about $26,000. Invesco Ltd. acquired a new position in shares of Aclaris Therapeutics during the 4th quarter worth about $28,000. Graham Capital Management L.P. acquired a new position in shares of Aclaris Therapeutics during the 4th quarter worth about $35,000. Commonwealth Equity Services LLC acquired a new position in shares of Aclaris Therapeutics during the 4th quarter worth about $36,000. Finally, Alpine Global Management LLC acquired a new position in shares of Aclaris Therapeutics during the 4th quarter worth about $38,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.